한글목차

세계의 정맥주사용 면역글로불린(IVIg) 시장은 2030년까지 340억 달러에 달할 전망

2023년에 191억 달러로 평가된 세계의 정맥주사용 면역글로불린(IVIg) 시장은 분석 기간 2023년부터 2030년까지 CAGR 8.6%로 성장할 전망이며, 2030년에는 340억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 IgA는 CAGR 10.7%로 성장을 지속하고, 분석 기간이 끝날 때까지 137억 달러에 이를 것으로 예상됩니다. IgE 부문의 성장률은 분석 기간 동안 CAGR 7.8%로 추정됩니다.

미국 시장은 51억 달러로 추정되는 반면 중국은 CAGR 8.0%로 성장할 것으로 예측

미국의 정맥주사용 면역글로불린(IVIg) 시장은 2023년 51억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 52억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 8.0%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 8.0%와 7.0%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 6.4%로 성장할 것으로 예측됩니다.

세계의 정맥주사용 면역글로불린(IVIg) 시장-주요 동향 및 촉진요인 요약

정맥주사용 면역글로불린(IVIg)는 치료에 중요한 성분이며 면역방어가 불충분한 사람들에게 필요한 항체를 제공합니다. 수천 명의 기증자의 혈장에서 얻은 IVIG는 다양한 병원체와 싸우는 데 필수적인 항체를 풍부하게 함유하고 있으며 면역 결핍 환자에게 필수적입니다. 체내에 필요한 항체를 보충함으로써 IVIG는 많은 감염에 대한 견고한 방어를 제공하고 체내에서 충분한 항체를 생산할 수 없는 환자에게 매우 중요합니다. 또한 IVIG는 자가면역 질환의 치료에도 중요한 역할을 합니다. 자가면역질환은 신체의 면역계가 실수로 자신의 세포를 공격하는 질병입니다. 고농도의 항체를 투여함으로써 IVIG는 이러한 잘못된 면역 반응을 완화하고 면역성 혈소판 감소증과 자가면역성 용혈성 빈혈과 같은 증상을 완화합니다.

IVIG의 투여는 일반적으로 임상 장소에서 정맥 내에서 수행되며, 투여량 및 투여 빈도는 환자 고유의 의료 필요 및 체중에 따라 면밀히 조정됩니다. 이러한 개별화 접근법을 통해 환자는 부작용을 최소화하면서 최적의 치료 효과를 얻을 수 있습니다. 그러나 IVIG 요법은 두통과 피로와 같은 경미한 증상에서 알레르기 반응과 같은 심각한 증상에 이르기까지 다양한 부작용이 수반될 수 있으므로 의료 종사자의 주의 깊은 모니터링과 이러한 부작용을 완화합니다. 하기 위한 사전 대책이 필요합니다. 최근의 동향에서는 피하 투여를 대신하는 약제의 개발, 항염증 작용이 강화된 유도체인 M254와 같은 기술 혁신이 보이고, 특히 자가면역 질환에 대해서, 종래의 IVIG보다 강력하고 인내 고용성 치료 옵션을 제공하는 것이 임상시험에서 기대됩니다.

IVIG 수요는 다양한 의료 용도, 희귀질환의 치료에 있어서의 효능, 만성 질환의 조기 개입 및 유지 요법에서의 사용 증가에 의해 견인되고 있습니다. IVIG 제조 기술의 진보는 IVIG의 안전성과 확장성을 향상시키고, 부작용을 완화하고, 환자의 전반적인 내약성을 향상시킵니다. 또한 세계 건강 활동과 면역학 전문센터가 IVIG를 국가 치료 지침에 통합하여 사용을 촉진합니다. 환자 광고와 교육은 이러한 필수적인 치료에 대한 접근을 요구하는 환자를 증가시키고 수요는 더욱 증가하고 있습니다. 규제당국의 지원, 특히 희소질환용 의약품에 대한 지원은 IVIG의 이용을 촉진하고, 기존 시장이나 신흥 시장에서도 이 중요한 치료제에 대한 접근을 향상시키고 있습니다. 이러한 요인은 현대 건강 관리에서 IVIG의 중요성 증가를 뒷받침하는 것으로, 세계 의료 현장에서의 역할 확대와 채용 확대를 시사합니다.

조사 대상 기업 예(주목의 24사)

• Bharat Serums and Vaccines Limited
• Biotest AG
• China Biologic Products, Inc.
• CSL Limited
• Grifols, SA
• Hualan Biological Engineering Inc.
• Kedrion SpA
• LFB Group
• Octapharma AG
• Shanghai RAAS Blood Products Co., Ltd.
• Shire plc
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향 및 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Intravenous Immunoglobulin (IVIg) Market to Reach US$34.0 Billion by 2030

The global market for Intravenous Immunoglobulin (IVIg) estimated at US$19.1 Billion in the year 2023, is expected to reach US$34.0 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2023-2030. IgA, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$13.7 Billion by the end of the analysis period. Growth in the IgE segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 8.0% CAGR

The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Intravenous Immunoglobulin (IVIg) Market - Key Trends and Drivers Summarized

Intravenous Immunoglobulin (IVIG) is a critical component in medical treatments, providing necessary antibodies to those with inadequate immune defenses. Derived from the plasma of thousands of donors, IVIG encompasses a wide array of antibodies essential for combating various pathogens, making it indispensable for individuals with immunodeficiency disorders. By supplementing the body's antibody requirement, IVIG offers robust protection against a multitude of infections, crucial for patients whose bodies cannot produce sufficient antibodies. Additionally, IVIG plays a significant role in treating autoimmune diseases, where the body's immune system erroneously attacks its own cells. By introducing a high concentration of antibodies, IVIG helps mitigate this misguided immune response, offering relief for conditions such as immune thrombocytopenia and autoimmune hemolytic anemia, among others.

The administration of IVIG is generally carried out intravenously in a clinical setting, where the dosage and frequency are meticulously tailored to the patient's specific medical needs and body weight. This personalized approach ensures that patients receive optimal treatment effectiveness with minimized side effects. However, IVIG therapy can be accompanied by adverse reactions ranging from mild symptoms like headaches and fatigue to more severe conditions such as allergic reactions, necessitating careful monitoring and preemptive measures by healthcare providers to mitigate these effects. Recent advancements have seen the development of subcutaneous alternatives and innovations like M254, a derivative with enhanced anti-inflammatory properties, showing promise in clinical trials for providing a more potent and better-tolerated treatment option than traditional IVIG, particularly for autoimmune conditions.

The demand for IVIG is driven by its diverse medical applications, effectiveness in treating rare diseases, and its increasing use in early intervention and maintenance therapy for chronic conditions. Technological advancements in IVIG production have enhanced its safety and scalability, reducing side effects and improving overall tolerability for patients. Additionally, global health initiatives and specialized immunology centers have integrated IVIG into national treatment guidelines, promoting its use. Patient advocacy and education have further increased demand, as more patients seek access to this essential treatment. Regulatory support, particularly for orphan drugs, has expedited the availability of IVIG, enhancing access to this crucial medication in both established and emerging markets. These factors collectively underscore the growing importance of IVIG in modern healthcare, pointing towards an expanded role and increased adoption in medical settings globally.

Select Competitors (Total 24 Featured) -

• Bharat Serums and Vaccines Limited
• Biotest AG
• China Biologic Products, Inc.
• CSL Limited
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Kedrion S.p.A.
• LFB Group
• Octapharma AG
• Shanghai RAAS Blood Products Co., Ltd.
• Shire plc
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Intravenous Immunoglobulin (IVIg) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Autoimmune Diseases Boosts Demand for IVIg Treatments
  • Advances in Extraction and Processing Technologies Improve IVIg Safety and Efficacy
  • Growing Geriatric Population Amplifies Need for Immunoglobulin Therapies
  • Expansion of Therapeutic Applications Beyond Immunodeficiency to Neurology
  • Rising Awareness and Diagnosis Rates of Rare Diseases Propel IVIg Usage
  • Shift Toward Home Care and Self-Administration Trends Enhance Patient Compliance
  • Advancements in Personalized Medicine Tailor IVIg Therapies to Individual Needs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Intravenous Immunoglobulin (IVIg) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for IgA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for IgE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for IgG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for IgM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for IgD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• JAPAN
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• CHINA
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• EUROPE
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• FRANCE
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• GERMANY
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2024 & 2030
  • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030

IV. COMPETITION